6 We are gathering speed: all three clinical programs are in Phase 3 with topline data expected in 2026 and Zenkuda is BLA ready *Based on the positive Phase 3 GLOW1 and GLOW2 studies in diabetic retinopathy, the BEACON study in retinal vein occlusion and the DAYLIGHT study in wet AMD ABC: antibody biopolymer conjugate; DR: diabetic retinopathy; RVO: retinal vein occlusion; wAMD: wet age-related macular degeneration KSI-101 Zenkuda Anti-VEGF ABC ® biologic KSI-501 Anti-IL-6, VEGF trap bispecific ABC ® biologic • Positive Phase 1b results in MESI • Phase 3 PEAK and PINNACLE studies actively enrolling • Topline data for the first 300- patient cohort in PEAK Dec. 2026 • 4 successful pivotal studies • BLA-ready in DR, RVO, wAMD* • Phase 3 DAYBREAK study in wAMD topline data Sept. 2026 • BLA filing expected in 2026 • Phase 3 DAYBREAK study in wAMD topline data Sept. 2026 • Phase 3 ALTO study in DME actively recruiting Anti-IL-6, VEGF trap bispecific protein Safe and potent control of MESI Strong immediacy and industry-leading durability Differentiated efficacy, strong immediacy and industry-leading durability